Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
29 studies found for:    19097774 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
Condition: Bone-Metastatic, Castration-Resistant Prostate Cancer
Intervention: Drug: KX2-391
2 Recruiting A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients
Condition: Melanoma
Intervention: Biological: NKT cells
3 Completed
Has Results
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
Conditions: Prostate Cancer;   Metastatic Castrate Resistant Prostate Cancer
Intervention: Drug: TRC105
4 Recruiting Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MK-3475;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed
5 Withdrawn Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
Condition: Pancreatic Cancer
Intervention: Drug: Tolfenamic acid + gemcitabine + radiation
6 Recruiting A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: SL-801
7 Recruiting Phase II Study of Perindopril and Regorafenib in mCRC
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Regorafenib;   Drug: Perindopril
8 Not yet recruiting A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Conditions: Non-Small-Cell Lung Cancer Metastatic;   Non-Small Cell Carcinoma of Lung, TNM Stage 4;   Nonsmall Cell Lung Cancer;   Non Small Cell Lung Cancer Recurrent
Interventions: Drug: Nivolumab;   Drug: nab-paclitaxel
9 Active, not recruiting Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
Conditions: Neoplasms, Unknown Primary;   CUP;   Metastatic Disease;   Poorly Differentiated Adenocarcinoma;   Poorly Differentiated Carcinoma;   Squamous Carcinoma Poorly Differentiated
Intervention:
10 Recruiting A Study of Coti-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Endometrial Cancer;   Cervical Cancer;   Peritoneal Cancer
Intervention: Drug: COTI2
11 Not yet recruiting Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
Condition: Small Cell Lung Cancer
Interventions: Drug: Topotecan;   Drug: Pembrolizumab
12 Recruiting Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Conditions: Cancer;   Pancreatic Cancer
Interventions: Procedure: Tumour Biopsy;   Other: Serial Collection of Plasma, Serum and Urine Samples
13 Recruiting Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI
Conditions: Colorectal Cancer;   Appendix Cancer;   Peritoneal Carcinomatosis
Intervention: Drug: Oxaliplatin
14 Not yet recruiting Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay
Conditions: Sarcoma;   Rectal Carcinoma;   Esophagus Cancer
Intervention: Radiation: Standard treatment
15 Recruiting Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Condition: Ovarian Cancer
Interventions: Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel
16 Not yet recruiting MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: MK-3475;   Drug: Docetaxel
17 Recruiting A Trial of TAS-114 in Combination With S-1
Condition: Advanced Solid Tumors
Interventions: Drug: TAS-114;   Drug: S-1
18 Recruiting An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel
Condition: Advanced Solid Tumors
Intervention: Drug: TAS-119
19 Recruiting Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
Conditions: Non-small Cell Lung Cancer Metastatic;   EGFR Activating Mutation
Interventions: Drug: Gefitinib;   Drug: gemcitabine;   Drug: carboplatin
20 Terminated Study of Low-Dose Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Intrahepatic Cholangiocarcinoma
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Gemcitabine;   Drug: Cisplatin;   Radiation: Low dose whole liver and portal lymph node basin radiotherapy

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.